Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

PDUFA VII Negotiations Completed, Commitment Letter Ratification Ongoing

Executive Summary

The US FDA, HHS and White House, as well as industry groups, now must sign off on the document.

You may also be interested in...



CBER Reorganization Aims To Fight Recruitment Challenges, Tackle Upcoming Gene Therapy Wave

A growing focus on real-world evidence and an expected infusion of user fee funding are among the reasons for the new office branches at US FDA’s biologics center.

FDA Creates Division To Support First Amendment Policy Development, Oversee Advertising Research

Multiple unfavorable court decisions have forced the agency to adjust its advertising enforcement strategies.

Bending PDUFA’s Cost Curve: PhRMA Looking For Sustainable Program Growth

Industry feels that sufficient program management tools are in place, but a PDUFA VII negotiator says they need more time to mature.

Related Content

Topics

Latest News
UsernamePublicRestriction

Register

PS144034

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel